Very early combination antiretroviral therapy in infants: Prospects for cure

Current Opinion in HIV and AIDS

Volumn 10, Issue 1, 2015, Pages 4-11

  Rainwater Lovett, Kaitlin ^a   Luzuriaga, Katherine ^b   Persaud, Deborah ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for Clinical and Translational Science   (United States)

Author keywords

HIV cure; HIV remission; Latent reservoir; Perinatal HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER;

CD4+ T LYMPHOCYTE; EARLY INTERVENTION; FEASIBILITY STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFANT DISEASE; LATENT PERIOD; NONHUMAN; PERINATAL INFECTION; REMISSION; REVACCINATION; REVIEW; VERY EARLY TREATMENT; VIRUS GENOME; VIRUS REPLICATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREVENTION AND CONTROL; TRANSMISSION; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84918543803     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000127     Document Type: Review

References (43)

1. UNAIDS. AIDS by the numbers. http://www.unaids.org/en/resources/documents/2013/name,88096,en.asp. [Accessed 4 December 2013]
2. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-1835.
3. Persaud D, Deveikis A, Gay H, et al. (2014). Very early combination anti-retroviral therapy in perinatal HIV infection: two case studies. 21st Conference on Retroviruses and Opportunistic Infections; 3-6 March 2014; Boston, MA, USA; abstract 75LB.
4. Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 2014; 161:319-327.
5. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013; 9:e1003347.
6. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.
7. Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013; 207:1694-1702.
8. Fauci AS, Marston HD, Folkers GK. An HIV cure: feasibility, discovery, and implementation. JAMA 2014; 312:335-336.
9. Schatorje EJ, Gemen EF, Driessen GJ, et al. Paediatric reference values for the peripheral T cell compartment. Scand J Immunol 2012; 75:436-444.
10. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112:973-980.
11. van GR, van Tilburg CM, Nibbelke EE, et al. Refined characterization and reference values of the pediatric T- and B-cell compartments. Clin Immunol 2009; 133:95-107.
12. Bunders MJ, van der Loos CM, Klarenbeek PL, et al. Memory CD4(+)CCR5(+) T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HIV-1. Blood 2012; 120:4383-4390.
13. Mold JE, Venkatasubrahmanyam S, Burt TD, et al. Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science 2010; 330:1695-1699.
14. Zhang X, Mozeleski B, Lemoine S, et al. CD4 T cells with effector memory phenotype and function develop in the sterile environment of the fetus. Sci Transl Med 2014; 6:238ra72.
15. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://www.who.int/hiv/pub/guidelines/arv2013/en/index.html. [Accessed 10 July 2013]
16. Cotton MF, Violari A, Otwombe K, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants with HIV: results from the children with HIV antiretroviral (CHER) randomized trial. Lancet 2013; 382:1555-1563.
17. Luzuriaga K, Tabak B, Garber M, et al. HIV Type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J Infect Dis 2014; 210:1529-1538.
18. Persaud D, Patel K, Karalius B, et al. Age at virologic control influences peripheral blood HIV reservoir size and serostatus in perinatally-infected adolescents. JAMA Pediatr 2014. [Epub ahead of print]
19. Ananworanich J, Puthanakit T, Suntarattiwong P, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 2014; 28:1015-1020.
20. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013; 9:e1003174.
21. Persaud D, Palumbo PE, Ziemniak C, et al. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS 2012; 26:1483-1490.
22. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605-1613.
23. Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410-1418.
24. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24:1598-1601.
25. Zanchetta M, Walker S, Burighel N, et al. Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy. J Infect Dis 2006; 193:1718-1727.
26. Hill AL, Rosenbloom DI, Fu F, et al. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A 2014; 111:13475-13480.
27. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
28. Bitnun A, Samson L, Chun TW, et al. Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood. Clin Infect Dis 2014; 59:1012-1019.
29. Brophy J, Chun T.W, Samson L, et al. (2014). Impact of early initiation of combination antiretroviral therapy on measure of virus in peripheral blood of vertically HIV-1 infected children. 20th International AIDS Conference; 19-25 July 2014; Melbourne, Australia; abstract PE47LB.
30. Cotugno N, Douagi I, Rossi P, et al. Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment. Clin Dev Immunol 2012; 2012: 805151.
31. Sutcliffe CG, Moss WJ. Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis 2010; 10:630-642.
32. Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000; 74:6984-6991.
33. Scott ZA, Chadwick EG, Gibson LL, et al. Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants. J Immunol 2001; 167:7134-7140.
34. Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155:540-551.
35. Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 381:2109-2117.
36. Mitchell C, Dross S, Beck IA, et al. Low concentrations of HIV-1 DNA at birth delays diagnosis, complicating identification of infants for antiretroviral therapy to potentially prevent the establishment of viral reservoirs. Clin Infect Dis 2014; 58:1190-1193.
37. Sutcliffe CG, van Dijk JH, Hamangaba F, et al. Turnaround time for early infant HIV diagnosis in rural Zambia: a chart review. PLoS One 2014; 9:e87028.
38. Persaud D, Palumbo P, Ziemniak C, et al. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007; 195:1402-1410.
39. Hatano H, Somsouk M, Sinclair E, et al. Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers. AIDS 2013; 27:2255-2260.
40. Garrido C, Margolis DM. Translational challenges in targeting latent HIV infection and the CNS reservoir problem. J Neurovirol 2014. [Epub ahead of print]
41. Whitney JB, Hill AL, Sanisetty S, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014; 512:74-77.
42. Dolgin E. New, intensive trials planned on heels of Mississippi HIV 'cure'. http://www.nature.com/nm/journal/v19/n4/full/nm0413-380.html. [Accessed 14 April 2013]
43. Shah SK, Persaud D, Wendler DS, et al. Research into a functional cure for HIV in neonates: the need for ethical foresight. Lancet Infect Dis 2014; 14:893-898.